SLC5A2 and lung disorder: Therefore, to gain a more comprehensive understanding of the association between SGLT2 and pulmonary diseases, building upon these studies, we hypothesize that gut microbiota and circulating metabolites may mediate the impact of SGLT2 inhibition on pulmonary diseases.